This page keeps track of new/upcoming treatment options for Duchenne Muscular Dystrophy (DMD). What’s in development? What’s promising? What’s available soon? Find out below… Current topics include CAP-1002, utrophin-based therapy, gene therapy, PF-06939926, and more.
SubscribeLast updated:
News
- Pfizer’s New Phase 1b Results of Gene Therapy in Ambulatory Boys with Duchenne Muscular Dystrophy (DMD) Support Advancement into Pivotal Phase 3 Study May 15, 2020
- Capricor Announces Positive Top-Line Final Results from HOPE-2 Study in Patients with Duchenne Muscular Dystrophy Treated with Lead Candidate CAP-1002 May 13, 2020
- New study indicates novel therapies for Duchenne muscular dystrophy Apr 25, 2020
- Santhera to Present Long-Term Data with Puldysa® (Idebenone) in Duchenne Muscular Dystrophy at Upcoming Medical Congresses Sep 17, 2019